Altex Industries (OTCMKTS:ALTX – Get Free Report) and Portage Biotech (NASDAQ:PRTG – Get Free Report) are both small-cap oils/energy companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings and institutional ownership.
Earnings & Valuation
This table compares Altex Industries and Portage Biotech’s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Altex Industries | $30,000.00 | 88.91 | -$130,000.00 | N/A | N/A |
| Portage Biotech | N/A | N/A | -$104.61 million | ($8.34) | -0.03 |
Altex Industries has higher revenue and earnings than Portage Biotech.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Altex Industries | -333.33% | -7.10% | -3.45% |
| Portage Biotech | N/A | -177.66% | -129.14% |
Volatility and Risk
Altex Industries has a beta of 0.23, meaning that its stock price is 77% less volatile than the S&P 500. Comparatively, Portage Biotech has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings for Altex Industries and Portage Biotech, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Altex Industries | 0 | 0 | 1 | 0 | 3.00 |
| Portage Biotech | 0 | 1 | 1 | 0 | 2.50 |
Altex Industries presently has a consensus price target of $56.00, indicating a potential upside of 23,729.79%. Portage Biotech has a consensus price target of $8.50, indicating a potential upside of 3,131.94%. Given Altex Industries’ stronger consensus rating and higher possible upside, research analysts plainly believe Altex Industries is more favorable than Portage Biotech.
Institutional & Insider Ownership
13.4% of Portage Biotech shares are held by institutional investors. 49.8% of Altex Industries shares are held by insiders. Comparatively, 42.1% of Portage Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Altex Industries beats Portage Biotech on 7 of the 10 factors compared between the two stocks.
About Altex Industries
Altex Industries, Inc., through its subsidiary, Altex Oil Corporation, owns interests in productive onshore oil and gas properties located in Utah and Wyoming. The company was incorporated in 1985 and is based in Denver, Colorado.
About Portage Biotech
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands.
Receive News & Ratings for Altex Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altex Industries and related companies with MarketBeat.com's FREE daily email newsletter.
